Neuroendocrine Tumor Diagnosis and Management: 68Ga-DOTATATE PET/CT.

Journal Article (Journal Article;Review)

OBJECTIVE: The purpose of this article is to provide a review of the use of 68Ga tetraazacyclododecanetetraacetic acid-DPhe1-Tyr3-octreotate (DOTATATE) PET/CT, a functional imaging modality for assessment of well-differentiated neuroendocrine tumors (NETs). It has become the preferred imaging modality for initial diagnosis, selection of patients for peptide receptor radionuclide therapy, and localization of unknown primary tumors. The National Comprehensive Cancer Network guideline has added 68Ga-DOTATATE PET/CT as an appropriate test in the management of NETs. CONCLUSION: In combination with FDG PET/CT, 68Ga-DOTATATE PET/CT can noninvasively assess tumor heterogeneity, especially in G2 and G3 NETs, for personalized management of patients.

Full Text

Duke Authors

Cited Authors

  • Sanli, Y; Garg, I; Kandathil, A; Kendi, T; Zanetti, MJB; Kuyumcu, S; Subramaniam, RM

Published Date

  • August 2018

Published In

Volume / Issue

  • 211 / 2

Start / End Page

  • 267 - 277

PubMed ID

  • 29975116

Electronic International Standard Serial Number (EISSN)

  • 1546-3141

Digital Object Identifier (DOI)

  • 10.2214/AJR.18.19881


  • eng

Conference Location

  • United States